Hypertension And Vascular Disease - USMLE Step 3

SECTION 1

Historical Context & Motivation

The recognition of hypertension as a distinct clinical entity evolved over more than a century of medical investigation. For decades, elevated arterial pressure was considered a benign, even necessary, physiological compensation in aging individuals, reflected in the once-popular term essential hypertension. This misconception persisted well into the mid-twentieth century, until landmark epidemiological studies and randomized clinical trials demonstrated that sustained elevations in blood pressure impose a devastating toll on the heart, brain, kidneys, and vasculature. The journey from ignorance to evidence-based management represents one of the greatest public health triumphs in modern medicine.

1896 • Invention of the Sphygmomanometer

Scipione Riva-Rocci developed the mercury sphygmomanometer, enabling the first non-invasive measurement of systolic blood pressure. Nikolai Korotkoff later refined the technique with auscultatory sounds for diastolic readings.

1948 • Framingham Heart Study Launched

This seminal longitudinal cohort study enrolled over 5,000 residents of Framingham, Massachusetts, and first established elevated blood pressure as a major independent risk factor for cardiovascular morbidity and mortality.

1967 • Veterans Affairs Cooperative Study

Edward Freis and colleagues demonstrated that pharmacological treatment of hypertension dramatically reduced stroke, heart failure, and death, providing the first randomized trial evidence supporting antihypertensive therapy.

2003 • JNC 7 Guidelines

The Seventh Report of the Joint National Committee introduced the concept of prehypertension (120–139/80–89 mmHg) and emphasized thiazide diuretics as first-line therapy, shaping treatment paradigms for over a decade.

2017 • ACC/AHA Revised Guidelines

The ACC/AHA guideline lowered the diagnostic threshold for hypertension to ≥130/80 mmHg based on SPRINT trial data, reclassifying millions of Americans and intensifying treatment targets for high-risk populations.

The central clinical question that hypertension management addresses is straightforward yet profoundly consequential: at what threshold does chronically elevated arterial pressure begin to inflict end-organ damage, and how can we intervene to reduce that burden? For the USMLE Step 3 examination, you must integrate the epidemiological, pathophysiological, pharmacological, and clinical dimensions of hypertension to make sound diagnostic and therapeutic decisions across diverse patient scenarios.

SECTION 2

Core Principles & Definitions

Understanding hypertension requires command of several interconnected physiological and clinical principles. Blood pressure is the product of cardiac output (CO) and systemic vascular resistance (SVR), a relationship that forms the cornerstone of all hemodynamic reasoning. Any sustained increase in either variable—or insufficient compensation to offset increases—results in chronic hypertension. The renin–angiotensin–aldosterone system (RAAS), sympathetic nervous system, renal sodium handling, and vascular endothelial function all converge to regulate this delicate balance.

Blood Pressure Classification

Per 2017 ACC/AHA guidelines: Normal (<120/80), Elevated (120–129/<80), Stage 1 HTN (130–139/80–89), Stage 2 HTN (≥140/≥90). Hypertensive crisis: >180/120 mmHg.

Primary vs. Secondary Hypertension

Primary (essential) hypertension accounts for ~90–95% of cases and has a multifactorial polygenic etiology. Secondary hypertension has an identifiable cause such as renal artery stenosis, pheochromocytoma, primary aldosteronism, or coarctation of the aorta.

End-Organ Damage

Chronic hypertension injures target organs: left ventricular hypertrophy, hypertensive retinopathy, nephrosclerosis, cerebrovascular disease, and aortic aneurysm. The degree of end-organ damage guides treatment urgency.

RAAS Axis

Juxtaglomerular cells release renin in response to decreased renal perfusion. Renin cleaves angiotensinogen to angiotensin I, which ACE converts to angiotensin II—a potent vasoconstrictor that stimulates aldosterone secretion, sodium retention, and sympathetic tone.

Vascular Remodeling

Sustained elevated pressure triggers smooth muscle hypertrophy, endothelial dysfunction, and accelerated atherosclerosis. Increased arterial stiffness elevates pulse pressure, creating a feed-forward cycle that amplifies cardiovascular risk.

✦

KEY TAKEAWAY

Think of the cardiovascular system as a plumbing network. Cardiac output is the volume of water the pump pushes through each minute, and systemic vascular resistance represents the caliber and stiffness of the pipes. Hypertension occurs when either the pump output is too high, the pipes are too narrow or rigid, or—most commonly—both factors conspire over years. Just as high-pressure water erodes pipes from the inside, chronic hypertension damages arteries and the organs they supply.

SECTION 3

Visual Explanation: Pathophysiology of Hypertension

The RAAS cascade begins with renin release from juxtaglomerular cells (left column), proceeds through angiotensin II generation (center), and results in vasoconstriction, aldosterone-mediated sodium retention, and ADH-induced volume expansion (right boxes). All pathways converge to elevate blood pressure. The dashed box below indicates major pharmacological intervention points.

The diagram above illustrates the central role of the renin–angiotensin–aldosterone system (RAAS) in blood pressure regulation. When renal perfusion pressure falls—whether from true hypovolemia, renal artery stenosis, or sympathetic activation—the juxtaglomerular apparatus releases renin, initiating a proteolytic cascade. Angiotensin II exerts its pro-hypertensive effects through three major mechanisms: direct arteriolar vasoconstriction (raising SVR), stimulation of aldosterone from the zona glomerulosa (increasing sodium and water reabsorption in the distal nephron), and enhancement of ADH secretion (expanding intravascular volume). The net effect is a rise in both cardiac output and systemic vascular resistance. Pharmacological agents such as ACE inhibitors, ARBs, calcium channel blockers, and diuretics each interrupt different nodes in this interconnected network, explaining why combination therapy is often required to achieve blood pressure goals.

SECTION 4

Hemodynamic Framework & Equations

The physiological basis of blood pressure can be distilled into several key equations that connect cardiac performance, vascular resistance, and clinical measurements. These relationships are tested frequently on USMLE Step 3, both directly and as the reasoning backbone for pharmacotherapy questions.

MEAN ARTERIAL PRESSURE

MAP = CO × SVR

Where MAP = mean arterial pressure (mmHg), CO = cardiac output (L/min), and SVR = systemic vascular resistance (dyn·s/cm⁵). This is the fundamental hemodynamic equation: any sustained change in MAP must reflect changes in CO, SVR, or both.

MAP ESTIMATION FROM CUFF BP

MAP ≈ DBP + ⅓(SBP − DBP)

Where SBP = systolic blood pressure and DBP = diastolic blood pressure. The ⅓ weighting reflects that diastole normally occupies approximately two-thirds of the cardiac cycle at resting heart rates.

CARDIAC OUTPUT

CO = HR × SV

Where HR = heart rate (beats/min) and SV = stroke volume (mL/beat). Beta-blockers lower CO primarily through HR reduction, while preload-reducing agents (e.g., diuretics, venodilators) lower SV.

POISEUILLE'S LAW (SIMPLIFIED)

R ∝ η × L / r⁴

Vascular resistance (R) is proportional to blood viscosity (η) and vessel length (L), and inversely proportional to the fourth power of the vessel radius (r). Even a small decrease in arteriolar radius—due to atherosclerosis, smooth muscle hypertrophy, or vasoconstriction—dramatically increases SVR.

⚕

CLINICAL PEARL

Poiseuille's law reveals why arteriolar radius is the dominant determinant of SVR: a 50% reduction in radius increases resistance by 16-fold (2⁴ = 16). This explains the outsized efficacy of vasodilators such as calcium channel blockers and the devastating vascular consequences of chronic vasoconstriction in hypertension. It also underscores why even modest improvements in endothelial function yield clinically meaningful BP reductions.

SECTION 5

Classification & Secondary Causes

Accurate classification of hypertension is essential for guiding workup intensity, treatment targets, and pharmacological selection. The 2017 ACC/AHA guidelines introduced a revised staging system based on data from the SPRINT trial, which demonstrated that targeting a systolic blood pressure below 120 mmHg in high-risk patients reduced cardiovascular events and all-cause mortality by approximately 25% compared to the traditional <140 mmHg target. The table below outlines the current classification system alongside recommended interventions.

Category	SBP (mmHg)	DBP (mmHg)	Recommended Action
Normal	<120	<80	Lifestyle promotion; reassess annually
Elevated	120–129	<80	Nonpharmacologic therapy (DASH diet, exercise, sodium restriction, weight loss)
Stage 1 HTN	130–139	80–89	Lifestyle + pharmacotherapy if 10-yr ASCVD risk ≥10% or clinical CVD/DM/CKD
Stage 2 HTN	≥140	≥90	Lifestyle + 2-drug combination therapy (typically ACEi/ARB + CCB or thiazide)
Hypertensive Crisis	>180	>120	Urgency: no end-organ damage → oral meds. Emergency: end-organ damage → IV agents in ICU

2017 ACC/AHA Blood Pressure Classification

This hub-and-spoke diagram illustrates the five most frequently tested causes of secondary hypertension on USMLE Step 3. Each spoke includes the key diagnostic clue or screening test. Renovascular disease is differentiated into fibromuscular dysplasia (young women) and atherosclerotic disease (older patients). Primary aldosteronism, pheochromocytoma, coarctation of the aorta, and obstructive sleep apnea round out the differential.

⚠

When to Suspect Secondary Hypertension

Investigate secondary causes when hypertension presents before age 30 or after age 55 without family history, when there is abrupt onset or rapid acceleration, when blood pressure is resistant to ≥3 agents (including a diuretic), or when there are suggestive laboratory abnormalities such as unprovoked hypokalemia, rising creatinine after ACE inhibitor initiation, or episodic symptoms (headache, palpitations, diaphoresis).

SECTION 6

Worked Example: Managing a Hypertensive Patient

Consider the following clinical vignette, representative of the patient management style tested on USMLE Step 3.

ℹ

Clinical Vignette

A 58-year-old African American male with type 2 diabetes mellitus and stage 3 CKD (eGFR 42 mL/min/1.73 m²) presents with a blood pressure of 162/98 mmHg confirmed on two separate office visits. His urine albumin-to-creatinine ratio is 320 mg/g. BMI is 32 kg/m². He currently takes metformin and atorvastatin. What is the most appropriate initial antihypertensive regimen?

Step-by-Step Clinical Reasoning

1
Step 1 — Classify the Hypertension

The patient's blood pressure of 162/98 mmHg places him in Stage 2 hypertension (SBP ≥140 or DBP ≥90 mmHg per ACC/AHA). Two-drug combination therapy is recommended at this stage.

Stage 2 HTN → Initiate combination therapy
2
Step 2 — Identify Compelling Indications

This patient has three compelling indications: diabetes mellitus, CKD with albuminuria, and African American race. CKD with proteinuria is the strongest indication for RAAS blockade, which reduces intraglomerular pressure and slows nephropathy progression.

ACEi or ARB mandatory for nephroprotection
3
Step 3 — Select the Drug Combination

For a patient with CKD and proteinuria, an ACE inhibitor (e.g., lisinopril) or ARB (e.g., losartan) is first-line. As a second agent, a dihydropyridine calcium channel blocker (e.g., amlodipine) is preferred in African American patients due to superior efficacy in this population. Alternatively, a thiazide-like diuretic (chlorthalidone) can be used, but the patient's eGFR of 42 mL/min suggests a loop diuretic may eventually be needed. However, at this eGFR thiazide-like diuretics still have some efficacy.

ACEi + amlodipine (or ACEi + chlorthalidone)
4
Step 4 — Set the BP Target

Per current guidelines, patients with diabetes, CKD, and elevated ASCVD risk should target a blood pressure of <130/80 mmHg. The SPRINT trial supports intensive lowering in high-risk patients, but the patient's CKD status warrants careful monitoring of potassium and creatinine after initiating RAAS blockade.

Target <130/80 mmHg; recheck BMP in 1–2 weeks
5
Step 5 — Counsel on Lifestyle Modifications

Recommend the DASH diet (rich in fruits, vegetables, low-fat dairy; <1,500 mg/day sodium in CKD), regular aerobic exercise (150 min/week), weight loss targeting BMI <30, limiting alcohol to ≤2 drinks/day, and smoking cessation if applicable. Each lifestyle modification can independently lower SBP by 4–11 mmHg.

Combined lifestyle changes can lower SBP by up to 20 mmHg

SECTION 7

Antihypertensive Drug Classes: Comparison & Selection

Selecting the appropriate antihypertensive agent requires balancing efficacy, side effect profiles, compelling indications, and contraindications. The following table provides a high-yield comparison of the four first-line drug classes, as well as two important secondary classes frequently encountered on USMLE Step 3.

Drug Class	Mechanism	Compelling Indications	Key Side Effects / Contraindications
ACE Inhibitors (lisinopril, enalapril)	Block ACE → ↓ Ang II, ↓ aldosterone, ↑ bradykinin	DM nephropathy, CKD with proteinuria, HFrEF, post-MI	Dry cough (bradykinin), hyperkalemia, angioedema. Contraindicated in pregnancy and bilateral RAS.
ARBs (losartan, valsartan)	Block AT₁ receptor → ↓ vasoconstriction, ↓ aldosterone	Same as ACEi; preferred if ACEi-intolerant (cough)	Hyperkalemia. Do NOT combine with ACEi (↑ renal failure, hyperkalemia per ONTARGET). Contraindicated in pregnancy.
Thiazide Diuretics (chlorthalidone, HCTZ)	Inhibit NaCl co-transporter in DCT → ↑ Na⁺/H₂O excretion	Osteoporosis (↓ Ca²⁺ excretion), elderly/isolated systolic HTN, African American patients	Hypokalemia, hyperuricemia (gout), hyponatremia, hyperglycemia, hypercalcemia. Less effective at eGFR <30.
CCBs (DHP) (amlodipine, nifedipine)	Block L-type Ca²⁺ channels in smooth muscle → vasodilation, ↓ SVR	Isolated systolic HTN, African American patients, angina	Peripheral edema, reflex tachycardia (short-acting). Avoid short-acting nifedipine in acute MI.
Beta-Blockers (metoprolol, carvedilol)	Block β₁ → ↓ HR, ↓ CO, ↓ renin release	HFrEF (carvedilol, metoprolol succinate, bisoprolol), post-MI, rate control in AF	Bradycardia, bronchospasm (non-selective), masked hypoglycemia in DM, fatigue. Not first-line for uncomplicated HTN.
MRAs (spironolactone, eplerenone)	Block aldosterone receptor → ↓ Na⁺ reabsorption, ↓ K⁺ loss	Resistant HTN (4th-line add-on), HFrEF, primary aldosteronism	Hyperkalemia (monitor with ACEi/ARB), gynecomastia (spironolactone). Avoid if K⁺ >5.0 or severe CKD.

Comparison of Major Antihypertensive Drug Classes

💊

TREATMENT ALGORITHM ESSENTIALS

Think of antihypertensive selection as a decision tree. First, determine whether there is a compelling indication (CKD, HF, post-MI, diabetes) that mandates a specific class. If none exists, choose from the four first-line agents—ACEi/ARB, CCB, or thiazide—based on patient demographics and comorbidities. For Stage 2 HTN, initiate two-drug combination therapy from the outset. If blood pressure remains uncontrolled on three agents (including a diuretic), the patient has resistant hypertension—add spironolactone and investigate secondary causes.

SECTION 8

Hypertensive Emergencies & Advanced Vascular Disease

A hypertensive emergency is defined as severely elevated blood pressure (typically >180/120 mmHg) with evidence of acute, ongoing end-organ damage including hypertensive encephalopathy, acute aortic dissection, acute coronary syndrome, acute pulmonary edema, eclampsia, or acute renal failure. This must be distinguished from hypertensive urgency, where blood pressure is severely elevated but there is no target organ damage. The distinction is critical because emergencies require immediate IV antihypertensive therapy in an ICU setting, while urgencies can be managed with oral medications and close outpatient follow-up.

Feature	Hypertensive Emergency	Hypertensive Urgency
BP Level	Usually >180/120 mmHg	Usually >180/120 mmHg
End-Organ Damage	Present	Absent
Setting	ICU with continuous arterial monitoring	ED observation or outpatient
Treatment Route	IV (nicardipine, nitroprusside, labetalol, clevidipine)	Oral (captopril, clonidine, labetalol PO)
BP Goal (first hour)	Reduce MAP by ≤25% in first hour (except aortic dissection: SBP <120 in 20 min)	Gradual reduction over 24–48 hours
Risk of Rapid Lowering	Cerebral hypoperfusion, watershed stroke, MI	Low risk, but still avoid precipitous drops

Hypertensive Emergency vs. Urgency

⚠

Aortic Dissection Exception

In acute aortic dissection, the BP target is more aggressive: reduce heart rate to <60 bpm and SBP to <120 mmHg within 20 minutes using IV beta-blockers (esmolol or labetalol) first, followed by a vasodilator (nitroprusside or nicardipine) if needed. Always initiate beta-blockade before vasodilation to prevent reflex tachycardia, which increases aortic shear stress (dP/dt).

The vascular sequelae of chronic hypertension extend well beyond the acute crises described above. Long-standing hypertension accelerates atherosclerosis through endothelial injury, promotes aortic aneurysm formation (particularly abdominal aortic aneurysm in elderly hypertensive smokers), and drives hypertensive nephrosclerosis—the second leading cause of end-stage renal disease in the United States. Understanding these downstream consequences reinforces why early, sustained blood pressure control is among the most impactful interventions in preventive medicine.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A 45-year-old woman presents with blood pressure readings of 134/86 mmHg on two separate office visits. She has no diabetes, no CKD, and her 10-year ASCVD risk is 6%. According to 2017 ACC/AHA guidelines, what is the appropriate classification of her blood pressure, and what is the recommended initial management?

Show answer

This patient has Stage 1 hypertension (SBP 130–139 or DBP 80–89 mmHg). Per ACC/AHA guidelines, pharmacotherapy is recommended for Stage 1 HTN only when the patient has clinical ASCVD, DM, CKD, or a 10-year ASCVD risk ≥10%. With a risk of only 6%, the appropriate initial management is nonpharmacologic lifestyle modifications alone: DASH diet, sodium restriction (<2,300 mg/day), regular aerobic exercise (150 min/week), and weight management. Blood pressure should be reassessed in 3–6 months, and pharmacotherapy should be initiated if BP remains above goal despite sustained lifestyle changes or if ASCVD risk increases.

Question 2: BASIC CALCULATION

A patient has a blood pressure of 150/90 mmHg and a cardiac output of 6 L/min. Calculate the mean arterial pressure (MAP) and the systemic vascular resistance (SVR) in mmHg·min/L.

Show answer

First, calculate MAP using the estimation formula: MAP ≈ DBP + ⅓(SBP − DBP) = 90 + ⅓(150 − 90) = 90 + 20 = 110 mmHg. Next, rearrange MAP = CO × SVR to solve for SVR: SVR = MAP ÷ CO = 110 ÷ 6 = 18.3 mmHg·min/L. To convert to conventional units (dyn·s/cm⁵), multiply by 80: 18.3 × 80 ≈ 1,467 dyn·s/cm⁵, which is elevated above the normal range of 800–1,200 dyn·s/cm⁵. This confirms that increased SVR is the predominant hemodynamic abnormality driving this patient's hypertension.

Question 3: INTERMEDIATE

A 32-year-old woman is found to have blood pressure of 168/102 mmHg. Serum potassium is 2.9 mEq/L and serum bicarbonate is 30 mEq/L. She is not taking diuretics. Plasma aldosterone is 28 ng/dL, and plasma renin activity (PRA) is 0.3 ng/mL/hr. What is the most likely diagnosis, and what confirmatory test should be ordered?

Show answer

The combination of severe hypertension in a young patient, unprovoked hypokalemia, metabolic alkalosis, elevated plasma aldosterone, and suppressed renin (aldosterone-to-renin ratio = 28/0.3 = 93, far exceeding the screening threshold of >30) is classic for primary aldosteronism (Conn syndrome or bilateral adrenal hyperplasia). The confirmatory test is the oral sodium loading test or saline infusion test; failure to suppress aldosterone below 5 ng/dL after volume expansion confirms autonomous aldosterone production. If confirmed, adrenal CT and adrenal vein sampling distinguish unilateral adenoma (treated surgically) from bilateral hyperplasia (treated with mineralocorticoid receptor antagonists).

Question 4: APPLIED

A 72-year-old man with a history of Stage 2 hypertension, type 2 diabetes, and HFrEF (EF 30%) presents to the emergency department with acute-onset tearing chest pain radiating to the back. Blood pressure is 210/118 mmHg in the right arm and 170/100 mmHg in the left arm. A CT angiogram reveals a Stanford Type B aortic dissection. What is the immediate pharmacological management?

Show answer

Acute aortic dissection requires immediate reduction of aortic shear stress (dP/dt) to limit propagation of the dissection flap. The first-line agent is an IV beta-blocker—esmolol (short-acting, titratable) or labetalol (combined alpha/beta blockade). The target is heart rate <60 bpm and SBP <120 mmHg within 20 minutes. If SBP remains elevated after adequate heart rate control, add an IV vasodilator such as nicardipine or nitroprusside. Critically, never administer a vasodilator before beta-blockade because the resulting reflex tachycardia increases dP/dt and worsens the dissection. Despite the patient's HFrEF, IV beta-blockade is still indicated in this life-threatening scenario, though careful dose titration is essential. Stanford Type B dissections confined to the descending aorta are generally managed medically unless there is evidence of malperfusion, rupture, or refractory pain.

Question 5: CRITICAL THINKING

A 55-year-old man with resistant hypertension (BP 156/94 mmHg on amlodipine 10 mg, lisinopril 40 mg, and chlorthalidone 25 mg daily) returns for follow-up. He reports medication adherence and has made lifestyle modifications. Serum potassium is 3.8 mEq/L, creatinine is 1.1 mg/dL, and the aldosterone-to-renin ratio is within normal limits. Explain the systematic approach to evaluating and managing this patient's resistant hypertension, including the next pharmacological step.

Show answer

True resistant hypertension requires systematic exclusion of pseudo-resistance: confirm adherence (pill counts, pharmacy refill records, or drug levels), exclude white-coat hypertension with ambulatory blood pressure monitoring (ABPM), optimize doses and timing, and ensure adequate diuretic therapy. Next, screen for secondary causes: renal artery stenosis (duplex ultrasound or MRA), primary aldosteronism (even though ARR was normal here, repeat testing off interfering medications may be warranted), pheochromocytoma (24-hour urine metanephrines), thyroid dysfunction, and obstructive sleep apnea (Epworth Sleepiness Scale, polysomnography). If all secondary causes are excluded and true resistance is confirmed, the evidence-based fourth-line agent is spironolactone 25–50 mg/day, supported by the PATHWAY-2 trial which demonstrated superiority of spironolactone over bisoprolol and doxazosin as add-on therapy for resistant hypertension. Potassium must be monitored closely given the combination with an ACE inhibitor. If spironolactone is not tolerated, consider amiloride, beta-blockers, hydralazine, or minoxidil. Renal denervation is an emerging interventional option but is not yet standard of care.

SUMMARY

Summary

Hypertension is defined as blood pressure ≥130/80 mmHg (2017 ACC/AHA) and affects nearly half of all adults. The fundamental hemodynamic equation MAP = CO × SVR underpins all pathophysiological reasoning. Primary (essential) hypertension accounts for 90–95% of cases, while secondary hypertension (renovascular disease, primary aldosteronism, pheochromocytoma, coarctation, OSA) should be suspected in young patients, those with sudden onset, or those with resistant hypertension. The RAAS axis is the central regulatory and therapeutic target, with ACE inhibitors and ARBs providing nephroprotection in CKD and diabetic nephropathy.

Treatment follows a stepwise approach: lifestyle modifications form the foundation for all stages, while pharmacotherapy is initiated based on stage and compelling indications. Stage 2 HTN warrants two-drug combination therapy at the outset. Hypertensive emergencies require IV therapy in the ICU with careful MAP reduction of no more than 25% in the first hour—except in aortic dissection, where SBP must reach <120 mmHg in 20 minutes with beta-blockers preceding vasodilators. Resistant hypertension (failure on 3 drugs including a diuretic) warrants screening for secondary causes and the addition of spironolactone as fourth-line therapy.